Changkun Mao,Chengpin Tao,Chao Yang et al.
Changkun Mao et al.
Background: Testicular cancer (TC) is the most common malignancy in young men, with incidence increasing globally, especially in high-income countries. Although survival has improved due to advances in diagnosis and treat...
Evaluation of the accuracy of cone-beam CT-based dose calculation for target volumes and organs at risk in left-sided breast cancer radiotherapy [0.03%]
Xiaoxiao Hou,Zhenglu Bai,Xiaoxiao Jin et al.
Xiaoxiao Hou et al.
Introduction: Accurate dose calculation is essential in breast cancer radiotherapy. This study aimed to evaluate the feasibility and accuracy of cone-beam CT (CBCT) images with HU-relative electron density (HU-RED) correc...
Correlation analysis of serum amyloid A, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and systemic immune-inflammation index with neoadjuvant therapy efficacy and prognosis in breast cancer [0.03%]
Yuanyuan Nong,Zhenzhen Zhou,Siyu Deng et al.
Yuanyuan Nong et al.
Background: Previous studies have extensively explored the relationships between the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) with treatment ef...
Two case reports of eosinophilic fasciitis with onset after immune checkpoint inhibitor cessation [0.03%]
Christopher F Theriau,Nancy Maltez,Niloufar Hosseini et al.
Christopher F Theriau et al.
Immune checkpoint inhibitors (ICIs) are known to cause a wide spectrum of immune-related adverse events (irAEs). Among these, eosinophilic fasciitis (EF) is a rare, fibrosing disorder causing inflammatory infiltration of subcutaneous fat an...
Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review [0.03%]
Caroline Lommer,Lila Schroeder,Caroline Amato et al.
Caroline Lommer et al.
Background: Breast cancer-related lymphedema (BCRL) is a common and life-long adverse event affecting ~20% of breast cancer survivors. As existing non-pharmacologic management is burdensome, expensive, and variably effect...
Case Report: Complete remission of refractory Langerhans cell sarcoma following CLAG-M chemotherapy and allogeneic hematopoietic stem cell transplant [0.03%]
Aubree Mades,Lydia Chow,Alireza Ghezavati et al.
Aubree Mades et al.
Langerhans Cell Sarcoma (LCS) is an extremely rare and aggressive neoplasm with limited consensus on optimal treatment. We report the case of a 56-year-old woman with refractory Langerhans Cell Histiocytosis (LCH) that transformed into Lang...
A comparative dosimetric evaluation of two image-guided calibration strategies for multi-isocenter total body irradiation: integrated fan-beam CT-based alignment versus sequential cone-beam CT-guided localization [0.03%]
Bo Gao,Yaling Hong,Junjing Yan et al.
Bo Gao et al.
Background: Image-guided radiotherapy (IGRT) is key to making sure the radiation dose is accurate when treating kids with multi-isocenter total body irradiation (TBI). Ensuring dose accuracy in pediatric multi-isocenter T...
A real-world comparison study of the efficacy of dual-target first-line rescue treatment of human epidermal growth factor receptor 2 positive advanced breast cancer: trastuzumab combined with pertuzumab versus trastuzumab combined with pyrotinib [0.03%]
Liang Zhang,Chao Li,Shubin Song et al.
Liang Zhang et al.
Introduction: Trastuzumab combined with pertuzumab (HP) is a first-line therapy for advanced breast cancer (ABC). However, trastuzumab combined with pyrotinib (HPyr) could also exert complementary and synergistic effects....
Sentinel lymph node biopsy versus lymphadenectomy in early-stage cervical cancer: a meta-analysis of oncologic outcomes and surgical morbidity [0.03%]
Chao Xiao,Siyuan Zeng,Luying Li et al.
Chao Xiao et al.
Objective: This study aimed to evaluate the oncologic safety of sentinel lymph node biopsy (SLNB) compared with systematic lymph node dissection (LND) in patients with early-stage cervical cancer and to determine whether ...
Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression [0.03%]
Yi Shi,Fangfang Chen,Yuanyuan Weng et al.
Yi Shi et al.
[This corrects the article DOI: 10.3389/fonc.2026.1741406.]. Keywords: CDC6; hepatocellular carcinoma; prote...
Published Erratum
Frontiers in oncology. 2026 Mar 4:16:1814738. DOI:10.3389/fonc.2026.1814738 2026